<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004315</url>
  </required_header>
  <id_info>
    <org_study_id>KUC1301</org_study_id>
    <nct_id>NCT01004315</nct_id>
  </id_info>
  <brief_title>A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean number of micturitions per 24 hours</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of urgency episodes per 24 hours</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of incontinence episodes per 24 hours</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>KUC-7483</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUC-7483</intervention_name>
    <arm_group_label>KUC-7483</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <arm_group_label>Tolterodine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a symptom of overactive bladder for more than 6 months.

          -  Patients who meet the following condition during the 3-day bladder diary period.

               -  the mean number of micturitions per 24 hours is ≥8 times

               -  the mean number of urgency episodes per 24 hours is ≥1 time

        Exclusion Criteria:

          -  Patients who are diagnosed as stress urinary incontinence are predominant.

          -  Patients with urinary calculus, interstitial cystitis, or clinically significant
             urinary tract infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuhiro Omori</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Development Department, Kissei pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan</name>
      <address>
        <city>Hokkaido,Tohoku,Kanto,Chubu,Kansai,Shikoku,Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <last_update_submitted>July 25, 2010</last_update_submitted>
  <last_update_submitted_qc>July 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <keyword>Overactive bladder</keyword>
  <keyword>Frequency</keyword>
  <keyword>Micturition</keyword>
  <keyword>Urgency</keyword>
  <keyword>Urge urinary incontinence</keyword>
  <keyword>OAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>p-Hydroxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

